Drugs / Al18F-NOTA-FAPI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05749302 | Jan 2023 → Mar 2025 | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-NOTA-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749302 ↗ |
| Modality | Diagnostic / imaging agent | “can be used as a broad-spectrum tumour developer for clinical PET/CT imaging for diagnosis and efficacy assessment of tumour patients.” NCT05749302 ↗ |
| Target | FAP | “18F-labelled tumour developer targeting FAP” NCT05749302 ↗ |